16 October 2020
Latham Advises Aligos Therapeutics in its IPO
Advising firms
Deal team
18 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Mark Roeder Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| John Williams | Latham & Watkins LLP | Associate | corporate | Bay Area |
| Tess Bloom | Latham & Watkins LLP | Associate | corporate | Bay Area |
| Madelyn Tarr | Latham & Watkins LLP | Associate | corporate | Bay Area |
| Natalie Robertson | Latham & Watkins LLP | Associate | corporate | Bay Area |
| Traci Biedermann | Latham & Watkins LLP | Associate | corporate | Orange County |
| Alan Tamarelli | Latham & Watkins LLP | Partner | technology transactions | New York |
| Chris Hazuka | Latham & Watkins LLP | Partner | technology transactions | Bay Area |
| Seth Appiah-Opoku | Latham & Watkins LLP | Associate | technology transactions | Boston |
| Kirt Switzer | Latham & Watkins LLP | Partner | tax | Bay Area |
| Janet Hsu | Latham & Watkins LLP | Associate | tax | Orange County |
| James Metz | Latham & Watkins LLP | Partner | benefits and compensation | Bay Area |
| Erik Ward | Latham & Watkins LLP | Associate | benefits and compensation | Bay Area |
| John Manthei | Latham & Watkins LLP | Partner | FDA regulatory | Washington, D.C. |
| Amy Speros | Latham & Watkins LLP | Associate | FDA regulatory | San Diego |
| Kiera Murphy | Latham & Watkins LLP | Associate | FDA regulatory | San Diego |
| Betty Pang | Latham & Watkins LLP | Counsel | healthcare regulatory | Bay Area |
| Heather Deixler | Latham & Watkins LLP | Counsel | healthcare regulatory | Bay Area |
Stated terms
- Stated value
- USD 150m ($150.0 million)
- What the figure measures
- Issue size
- Client
- Aligos Therapeutics, Inc.Issuer
- Counterparties
- Not stated